← Back to Clinical Trials
Recruiting NCT03417960

NCT03417960 Accelerated iTBS for Post Partum Depression

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03417960
Status Recruiting
Phase
Sponsor Medical University of South Carolina
Condition Post Partum Depression
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2018-01-24
Primary Completion 2027-08-30

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 50 Years
Study Type INTERVENTIONAL
Interventions
iTBS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2018-01-24 with a primary completion date of 2027-08-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Study 1: The investigators are studying the feasibility and tolerability of 10x/day intermittent theta burst (excitatory) transcranial magnetic stimulation to the left dorsolateral prefrontal cortex over the course of 6 days for women with post-partum depression. The investigators further aim to characterize the anticipated anti-depressant effect of this treatment paradigm. Study 2: The investigators are studying the feasibility and tolerability of 12 sessions/day of intermittent theta burse (excitatory) transcranial magnetic stimulation to the left dorsolateral prefrontal cortex over 5 days for women with post-partum depression. The investigators aim to compare the two different treatment schedules.

Eligibility Criteria

Inclusion Criteria: 1. Participants must be able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments. 2. Participants must be over the age of 18. 3. Participants must meet criteria for post-partum depression: a) onset of symptoms in the first year postpartum 4. Participants must have a HRSD17 greater than or equal to 14 at baseline. Exclusion Criteria: 1. Participants must not be pregnant. 2. Participants must not meet moderate or severe use disorder of any substance with the exception of Tobacco Use Disorder. 3. Participants must not have current psychotic symptoms. 4. Participants must not have a history of dementia or other cognitive impairment. 5. Participants must not have active suicidal ideation requiring hospitalization or a suicide attempt within the past 3 months. 6. Participants must not have any contraindications to receiving rTMS (e.g. metal implanted above the neck, history of seizure, any known brain lesion). 7. Participants must not have any unstable general medical conditions. 8. Participants must not have had eclampsia during pregnancy.

Contact & Investigator

Central Contact

Lisa McTeague, PhD

✉ mcteague@musc.edu

📞 843-792-8274

Frequently Asked Questions

Who can join the NCT03417960 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Post Partum Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03417960 currently recruiting?

Yes, NCT03417960 is actively recruiting participants. Contact the research team at mcteague@musc.edu for enrollment information.

Where is the NCT03417960 trial being conducted?

This trial is being conducted at Charleston, United States.

Who is sponsoring the NCT03417960 clinical trial?

NCT03417960 is sponsored by Medical University of South Carolina. The trial plans to enroll 40 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology